Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials-Reference-Cited by-同舟云学术

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials

Published:2018-06-12 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Yan Yi-Dan,Zhang Chi,Shen Long,Su Ying-Jie,Liu Xiao-Yan,Wang Li-Wei,Gu Zhi-Chun

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference31 articles.

1. Oral apixaban for the treatment of acute venous thromboembolism;Agnelli;N. Engl. J. Med.,2013

2. Oral rivaroxaban for symptomatic venous thromboembolism;Bauersachs;N. Engl. J. Med.,2010

3. Cancer-associated thrombosis: prevention and treatment;Brose;Curr. Oncol.,2008

4. Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: a meta-analysis study;Brunetti;Int. J. Cardiol.,2017

5. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism;Büller;N. Engl. J. Med.,2013

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation;Pharmaceutics;2024-07-30

2. Direct-Acting Oral Anticoagulant Therapy in Cancer Patients—A Review;Cancers;2023-05-10

3. The Efficacy and Safety of Direct Oral Anticoagulants for The Treatment of Venous Thrombosis in Cancer Using Fuzzy PROMETHEE;2023 Advances in Science and Engineering Technology International Conferences (ASET);2023-02-20

4. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer;Frontiers in Immunology;2021-12-03

5. Direct acting oral anticoagulants versus low molecular weight heparin for primary thromboprophylaxis in cancer patients;Medwave;2021-05-27